Brussels-Sana
The drug regulator in Europe announced today that it has added a rare neurological disorder known as Guillain-Barré syndrome as a possible side effect of the Johnson & Johnson vaccine against COVID-19.
Reuters quoted the European Union Medicines Control Authority as saying in a statement that, “After evaluating the available data and reviewing 108 cases registered in the world, the Safety Committee concluded that there may be a relationship between the Johnson & Johnson vaccine to prevent corona virus disease and Guillain-Barré syndrome.”
Guillain-Barré syndrome is a rare medical condition in which the human immune system attacks the nerves as a result of a disturbance in the orders issued by the brain. The first symptoms usually appear in the form of tingling in the limbs and weakness, and these symptoms quickly spread until the entire body is paralyzed. This syndrome is a medical emergency if it is severe Where the patients receive treatment in the hospital.
